{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:29:05Z","timestamp":1793946545810,"version":"4.8.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360032"],"award-info":[{"award-number":["82360032"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017534","name":"Inner Mongolia Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017534","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105433","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T18:14:55Z","timestamp":1781460895000},"page":"105433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Proteomics as a theranostic compass in BCR::ABL1-negative myeloproliferative neoplasms: Integrating biomarker discovery with therapeutic stratification"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5419-9463","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2658-0803","authenticated-orcid":false,"given":"Yan-Qiu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2026.105433_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100587","article-title":"Functional Impact of Protein-RNA Variation in Clinical Cancer Analyses","volume":"22","author":"Arad","year":"2023","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.critrevonc.2026.105433_bib2","series-title":"JAK2 in Myeloproliferative Neoplasms: Still a Protagonist","author":"Bader","year":"2022"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105433_bib3","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.cell.2024.04.013","article-title":"Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging","volume":"187","author":"Bandyopadhyay","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105433_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12014-023-09424-x","article-title":"Mass spectrometry-based proteomics as an emerging tool in clinical laboratories","author":"Birhanu","year":"2023","journal-title":"Clin. Proteom. Engl."},{"key":"10.1016\/j.critrevonc.2026.105433_bib5","series-title":"Correction: Proteomic screening identifies PF4\/Cxcl4 as a critical driver of myelofibrosis","first-page":"1273","author":"Capitanio","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105433_bib6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1078-0432.CCR-23-0163","article-title":"Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable","author":"Codilupi","year":"2024","journal-title":"Clin. Cancer Res. U. S."},{"key":"10.1016\/j.critrevonc.2026.105433_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105433_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s40364-025-00865-0","article-title":"Combinatorial BCL2\/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis","author":"Coltro","year":"2025","journal-title":"Biomark. Res. Engl."},{"key":"10.1016\/j.critrevonc.2026.105433_bib9","series-title":"Spatial transcriptomic approaches for characterising the bone marrow landscape: Pitfalls and potential","first-page":"291","author":"Cooper","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105433_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-023-00875-x","article-title":"Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2(V617F) myeloproliferative neoplasms","author":"Courdy","year":"2023","journal-title":"Blood Cancer J. U. S."},{"key":"10.1016\/j.critrevonc.2026.105433_bib11","article-title":"Diagnostics and correction of batch effects in large-scale proteomic studies: a tutorial","author":"Cuklina","year":"2021","journal-title":"Mol. Syst. Biol. Ger."},{"key":"10.1016\/j.critrevonc.2026.105433_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102561","article-title":"Proteomic profiling links complement activation to thrombosis in JAK2V617F myeloproliferative neoplasms","volume":"62","author":"De Moner","year":"2025","journal-title":"Transl. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105433_bib13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1055\/a-2498-4849","article-title":"Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis","volume":"125","author":"De Moner","year":"2025","journal-title":"Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105433_bib14","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1021\/acs.jproteome.1c00657","article-title":"Advances and Utility of the Human Plasma Proteome","volume":"20","author":"Deutsch","year":"2021","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.critrevonc.2026.105433_bib15","doi-asserted-by":"crossref","first-page":"8774","DOI":"10.1038\/s41467-025-64501-z","article-title":"Multicenter evaluation of label-free quantification in human plasma on a high dynamic range benchmark set","author":"Distler","year":"2025","journal-title":"Nat. Commun. Engl."},{"key":"10.1016\/j.critrevonc.2026.105433_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1240115","article-title":"Post-translational modifications and their implications in cancer","volume":"13","author":"Dutta","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105433_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-024-07549-z","article-title":"Author Correction: large-scale plasma proteomics comparisons through genetics and disease associations","author":"Eldjarn","year":"2024","journal-title":"Nat. Engl."},{"key":"10.1016\/j.critrevonc.2026.105433_bib18","first-page":"176","article-title":"Regulation (EU) 2017\/746 of 5 April 2017 on in vitro diagnostic medical devices","volume":"117","author":"European Parliament and Council of the European Union","year":"2017"},{"key":"10.1016\/j.critrevonc.2026.105433_bib19","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1182\/bloodadvances.2025016898","article-title":"Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase","author":"Fiskus","year":"2025","journal-title":"Blood Adv. U. S."},{"key":"10.1016\/j.critrevonc.2026.105433_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.961448","article-title":"Pre-analytical processing of plasma and serum samples for combined proteome and metabolome analysis","author":"Gegner","year":"2022","journal-title":"Front. Mol. Biosci. Switz."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105433_bib21","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14737140.2022.2093192","article-title":"Targeting the PI3K pathway in myeloproliferative neoplasms","volume":"22","author":"Gerds","year":"2022","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.critrevonc.2026.105433_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-021-01116-z","article-title":"Molecular pathogenesis of the myeloproliferative neoplasms","author":"Greenfield","year":"2021","journal-title":"J. Hematol. Oncol. Engl."},{"key":"10.1016\/j.critrevonc.2026.105433_bib23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41586-025-08584-0","article-title":"Mass-spectrometry-based proteomics: from single cells to clinical applications","author":"Guo","year":"2025","journal-title":"Nat. Engl."},{"key":"10.1016\/j.critrevonc.2026.105433_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174323","article-title":"Revisiting circulating extracellular matrix fragments as disease markers in myelofibrosis and related neoplasms","author":"Hasselbalch","year":"2023","journal-title":"Cancers (Basel). Switz."},{"key":"10.1016\/j.critrevonc.2026.105433_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172256","article-title":"Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms","author":"He","year":"2024","journal-title":"J. Clin. Invest. U. S."},{"key":"10.1016\/j.critrevonc.2026.105433_bib26","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1182\/bloodadvances.2021005491","article-title":"PD-1 inhibition in advanced myeloproliferative neoplasms","author":"Hobbs","year":"2021","journal-title":"Blood Adv. U. S."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105433_bib27","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3324\/haematol.2024.285598","article-title":"Different inflammatory, fibrotic, and immunological signatures between pre-fibrotic and overt primary myelofibrosis","volume":"110","author":"Jung","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105433_bib28","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/bloodadvances.2023012016","article-title":"Platelet proteomic profiling reveals potential mediators of immunothrombosis and proteostasis in myeloproliferative neoplasms","author":"Kelliher","year":"2024","journal-title":"Blood Adv. U. S."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105433_bib29","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/mas.21781","article-title":"Advances in data-independent acquisition mass spectrometry towards comprehensive digital proteome landscape","volume":"42","author":"Kitata","year":"2023","journal-title":"Mass. Spectrom. Rev."},{"key":"10.1016\/j.critrevonc.2026.105433_bib30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41467-024-55643-7","article-title":"RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia","author":"Kong","year":"2025","journal-title":"Nat. Commun. Engl."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105433_bib31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/ajh.26935","article-title":"Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms","volume":"98","author":"Kong","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"23-24","key":"10.1016\/j.critrevonc.2026.105433_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202100153","article-title":"Targeted liquid chromatography-tandem mass spectrometry analysis of proteins: basic principles, applications, and perspectives","volume":"21","author":"Kulyyassov","year":"2021","journal-title":"Proteomics"},{"issue":"768","key":"10.1016\/j.critrevonc.2026.105433_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj7552","article-title":"A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis","volume":"16","author":"Li","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105433_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3324\/haematol.2023.283987","article-title":"Pathogenesis and management of high molecular risk myeloproliferative neoplasms","volume":"110","author":"Ling","year":"2025","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105433_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2024.100712","article-title":"Acquisition and analysis of DIA-based proteomic data: a comprehensive survey in 2023","volume":"23","author":"Lou","year":"2024","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.critrevonc.2026.105433_bib36","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","author":"Luque Paz","year":"2021","journal-title":"Blood Adv. U. S."},{"key":"10.1016\/j.critrevonc.2026.105433_bib37","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s43587-024-00647-7","article-title":"Epigenetic and proteomic signatures associate with clonal hematopoiesis expansion rate","author":"Mack","year":"2024","journal-title":"Nat. Aging U. S."},{"key":"10.1016\/j.critrevonc.2026.105433_bib38","series-title":"Clonal architecture evolution in Myeloproliferative Neoplasms: From a driver mutation to a complex heterogeneous mutational and phenotypic landscape","first-page":"957","author":"Maslah","year":"2023"},{"key":"10.1016\/j.critrevonc.2026.105433_bib39","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/bloodadvances.2020003303","article-title":"CAMK2G is identified as a novel therapeutic target for myelofibrosis","author":"Miyauchi","year":"2022","journal-title":"Blood Adv. U. S."},{"key":"10.1016\/j.critrevonc.2026.105433_bib40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11899-024-00739-6","article-title":"Prognostic and predictive models in myelofibrosis","author":"Mora","year":"2024","journal-title":"Curr. Hematol. Malig. Rep. U. S."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105433_bib41","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000818","article-title":"Machine learning improves risk stratification in myelofibrosis: an analysis of the spanish registry of myelofibrosis","volume":"7","author":"Mosquera-Orgueira","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.critrevonc.2026.105433_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109517","article-title":"Prothrombotic profiles in myelofibrosis: fibrinogen oxidation and the beneficial effects of ruxolitinib","volume":"256","author":"Nencini","year":"2025","journal-title":"Thromb. Res."},{"key":"10.1016\/j.critrevonc.2026.105433_bib43","article-title":"Recent developments in clinical plasma proteomics-applied to cardiovascular research","author":"Palstrom","year":"2022","journal-title":"Biomed. Switz."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105433_bib44","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ajh.27282","article-title":"SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms","volume":"99","author":"Pandey","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105433_bib45","article-title":"Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia","volume":"5","author":"Pino","year":"2024","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105433_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184654","article-title":"Exploring the molecular landscape of myelofibrosis, with a focus on ras and mitogen-activated protein (MAP) kinase signaling","author":"Reynolds","year":"2023","journal-title":"Cancers (Basel). Switz."},{"key":"10.1016\/j.critrevonc.2026.105433_bib47","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2767-9764.CRC-23-0010","article-title":"Targeting CHAF1B enhances IFN activity against myeloproliferative neoplasm cells","author":"Saleiro","year":"2023","journal-title":"Cancer Res. Commun. U. S."},{"key":"10.1016\/j.critrevonc.2026.105433_bib48","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/s41467-022-29381-7","article-title":"Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms","author":"Saleiro","year":"2022","journal-title":"Nat. Commun. Engl."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105433_bib49","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s13023-024-03462-w","article-title":"A micro-costing study of mass-spectrometry based quantitative proteomics testing applied to the diagnostic pipeline of mitochondrial and other rare disorders","volume":"19","author":"Santos Gonzalez","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105433_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jmoldx.2024.10.003","article-title":"Analysis of Molecular Testing for Suspected Myeloproliferative Neoplasm at a Hybrid Community-Academic Health System","volume":"27","author":"Stone","year":"2025","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2026.105433_bib51","series-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","first-page":"1","author":"Talpaz","year":"2021"},{"key":"10.1016\/j.critrevonc.2026.105433_bib52","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1182\/bloodadvances.2021005344","article-title":"Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells","author":"Tan","year":"2022","journal-title":"Blood Adv. U. S."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105433_bib53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105433_bib54","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105433_bib55","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105433_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01877-0","article-title":"MTAP-related increased erythroblast proliferation as a mechanism of polycythaemia vera","author":"Tipgomut","year":"2021","journal-title":"Sci. Rep. Engl."},{"key":"10.1016\/j.critrevonc.2026.105433_bib57","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-23-3468","article-title":"Plasma proteomic signature predicts myeloid neoplasm risk","author":"Tran","year":"2024","journal-title":"Clin. Cancer Res. U. S."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105433_bib58","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1021\/acs.jproteome.4c00363","article-title":"A framework for quality control in quantitative proteomics","volume":"23","author":"Tsantilas","year":"2024","journal-title":"J. Proteome Res."},{"issue":"88","key":"10.1016\/j.critrevonc.2026.105433_bib59","first-page":"37286","article-title":"Medical devices; laboratory developed tests (Final Rule)","volume":"89","author":"U.S. Food and Drug Administration","year":"2024","journal-title":"Fed. Regist."},{"key":"10.1016\/j.critrevonc.2026.105433_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.crmeth.2022.100288","article-title":"Experimental reproducibility limits the correlation between mRNA and protein abundances in tumor proteomic profiles","author":"Upadhya","year":"2022","journal-title":"Cell. Rep. Methods U. S."},{"key":"10.1016\/j.critrevonc.2026.105433_bib61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/hematology.2022000339","article-title":"Molecular prognostication in Ph-negative MPNs in 2022","author":"Vannucchi","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program. U. S."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105433_bib62","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41592-021-01205-4","article-title":"DOME: recommendations for supervised machine learning validation in biology","volume":"18","author":"Walsh","year":"2021","journal-title":"Nat. Methods"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105433_bib63","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acsmeasuresciau.4c00007","article-title":"A tutorial review of labeling methods in mass spectrometry-based quantitative proteomics","volume":"4","author":"Wang","year":"2024","journal-title":"ACS Meas. Sci. Au"},{"key":"10.1016\/j.critrevonc.2026.105433_bib64","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/s41467-025-56935-2","article-title":"Comparative studies of 2168 plasma proteins measured by two affinity-based platforms in 4000 Chinese adults","author":"Wang","year":"2025","journal-title":"Nat. Commun. Engl."},{"key":"10.1016\/j.critrevonc.2026.105433_bib65","article-title":"Proteomic-based platelet activation-associated protein SELP may be a novel biomarker for coagulation and prognostic in essential thrombocythemia","author":"Wang","year":"2023","journal-title":"J. Clin. Med. Switz."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105433_bib66","article-title":"A proteomics-driven machine learning tool for distinguishing ET from pre-PMF","volume":"146","author":"Wen","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105433_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100168","article-title":"Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis","volume":"20","author":"Wik","year":"2021","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.critrevonc.2026.105433_bib68","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1038\/s41467-023-42101-z","article-title":"Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis","author":"Wildschut","year":"2023","journal-title":"Nat. Commun. Engl."},{"key":"10.1016\/j.critrevonc.2026.105433_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-023-00829-3","article-title":"Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression","author":"Yan","year":"2023","journal-title":"Blood Cancer J. U. S."},{"key":"10.1016\/j.critrevonc.2026.105433_bib70","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s10238-024-01350-y","article-title":"Multi-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis","author":"Zhang","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105433_bib71","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","author":"Zhou","year":"2024","journal-title":"Signal. Transduct. Target. Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:46:48Z","timestamp":1793944008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":71,"alternative-id":["S1040842826003203"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105433","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteomics as a theranostic compass in BCR::ABL1-negative myeloproliferative neoplasms: Integrating biomarker discovery with therapeutic stratification","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105433"}}